Tekla Life Sciences Investors (HQL) Earnings History
Profitable30 years of earnings data (1996–2025) · Positive TTM net income
Loading earnings history...
Tekla Life Sciences Investors (HQL) Earnings Overview
As of June 30, 2026, Tekla Life Sciences Investors (HQL) reported trailing twelve-month net income of $139M, reflecting +274.7% year-over-year growth. The company earned $4.59 per diluted share over the past four quarters, with a net profit margin of 99.1%.
Looking at the long-term picture, HQL's historical earnings data spans multiple years. The company achieved its highest annual net income of $123M in fiscal 2020.
Tekla Life Sciences Investors maintains industry-leading profitability with a gross margin of 100.0%, operating margin of 99.1%, and net margin of 99.1%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including HQH ($241M net income, 1717.4% margin), XBIO (-$2M net income, -90.1% margin), GHC ($298M net income, 6.0% margin), HQL has room to improve margins relative to the peer group. Compare HQL vs HQH →
HQL Earnings vs Peers
Earnings metrics vs comparable public companies
HQL Historical Earnings Data (1996–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $86M | +282.9% | $86M | $2.96 | 99.1% | 99.1% |
| 2023 | $22M | +121.4% | -$5M | $0.79 | 56.8% | -13.3% |
| 2022 | -$105M | -262.1% | -$105M | $-4.07 | -328.3% | -328.3% |
| 2021 | $65M | -47.6% | $65M | $2.66 | 143.3% | 143.3% |
| 2020 | $123M | +274.6% | $123M | $5.16 | 314.9% | 314.9% |
| 2019 | -$70M | -345.9% | -$3M | $-3.04 | -2887.8% | -118.0% |
| 2018 | $29M | -58.2% | -$4M | $1.28 | 1443.4% | -181.6% |
| 2017 | $69M | +675.7% | -$4M | $3.21 | 98.2% | -5.6% |
| 2016 | -$12M | -129.4% | -$4M | $-0.57 | -189.3% | -60.3% |
| 2015 | $40M | -54.6% | -$5M | $2.06 | 3062.1% | -357.0% |
| 2014 | $89M | +5.5% | -$4M | $4.70 | 10181.2% | -429.5% |
| 2013 | $85M | +9.0% | -$3M | $5.64 | 16380.1% | -613.4% |
| 2012 | $78M | +107.2% | -$1M | $5.38 | 3620.0% | -59.8% |
| 2011 | $37M | +267.7% | -$4M | $2.57 | 6573.7% | -666.7% |
| 2010 | $10M | +147.0% | -$2M | $0.47 | 559.9% | -107.7% |
| 2009 | -$22M | -136.0% | -$3M | $-0.99 | -4710.9% | -684.8% |
| 2008 | $60M | +19.3% | -$3M | $2.86 | 3607.8% | -174.9% |
| 2007 | $51M | +335.6% | -$2M | $2.52 | 1753.8% | -59.4% |
| 2006 | -$21M | -147.9% | -$1M | $-1.11 | -932.2% | -58.3% |
| 2005 | $45M | +525.1% | -$3M | $3.55 | 5029.2% | -291.0% |
| 2004 | $7M | -81.5% | -$3M | $0.59 | 2237.5% | -959.4% |
| 2003 | $39M | +176.6% | -$2M | $3.38 | 6331.1% | -383.6% |
| 2002 | -$50M | +47.0% | -$3M | $-4.84 | -5362.8% | -268.1% |
| 2001 | -$95M | -212.8% | -$2M | $-10.20 | -5368.9% | -109.6% |
| 1998 | -$30M | -300.0% | -$2M | $-4.17 | -21700.0% | -1250.0% |
| 1997 | $15M | -30.4% | -$2M | $2.17 | 4746.9% | -478.1% |
| 1996 | $22M | - | -$1M | $3.26 | 5192.9% | -350.0% |
Download Data
Export HQL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HQL — Frequently Asked Questions
Quick answers to the most common questions about buying HQL stock.
What is HQL earnings per share (EPS)?
HQL trailing twelve-month (TTM) diluted EPS is $4.59, reflecting +274.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1996 to 2025 is available in the table on this page.
What is Tekla Life Sciences Investors's net income?
Tekla Life Sciences Investors (HQL) trailing twelve-month net income is $139M as of 2025. Earnings grew +274.7% year-over-year. Tekla Life Sciences Investors has been profitable for 2 consecutive years.
Is HQL profitable?
Yes, HQL is profitable with a TTM net income of $139M and a net profit margin of +99.1%. Tekla Life Sciences Investors has generated profits for 2 consecutive years.
What is HQL's earnings growth rate?
HQL compound annual EPS growth rates (CAGR): 1-Year: +274.7%, 3-Year: +3.6%, 5-Year: N/A, 10-Year: -4.5%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1996 to 2025.
What are HQL's profit margins?
Tekla Life Sciences Investors net profit margin is +99.1%, operating margin is +99.1%, and gross margin is +100.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +18.7%.
Is HQL growing earnings?
Yes, HQL earnings are accelerating — EPS growth of +274.7% exceeds the 5-year CAGR of N/A. TTM net income reached $139M. Earnings momentum is strengthening.
What was HQL's best earnings year?
Tekla Life Sciences Investors's highest annual net income on record is $123M, achieved in fiscal year 2020. Earnings history on this page spans 1996 to 2025 and includes all annual and quarterly figures.
What were HQL's earnings last quarter?
HQL's most recent reported quarter was Q2 2026. Net income was $65M with diluted EPS of $2.15. For a full breakdown of all quarters, see the quarterly earnings table on this page.